These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 17170032)

  • 1. Clinical trials bureaucracy: unintended consequences of well-intentioned policy.
    Califf RM
    Clin Trials; 2006; 3(6):496-502. PubMed ID: 17170032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulatory perspectives on data monitoring.
    O'Neill RT
    Stat Med; 2002 Oct; 21(19):2831-42. PubMed ID: 12325099
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance and challenges of studying marketed drugs: what is a phase IV study? Common clinical research designs, registries, and self-reporting systems.
    Glasser SP; Salas M; Delzell E
    J Clin Pharmacol; 2007 Sep; 47(9):1074-86. PubMed ID: 17766697
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific barriers to the conduct of randomized trials.
    Duley L; Antman K; Arena J; Avezum A; Blumenthal M; Bosch J; Chrolavicius S; Li T; Ounpuu S; Perez AC; Sleight P; Svard R; Temple R; Tsouderous Y; Yunis C; Yusuf S
    Clin Trials; 2008; 5(1):40-8. PubMed ID: 18283079
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trials in vulnerable populations.
    Cook D; Moore-Cox A; Xavier D; Lauzier F; Roberts I
    Clin Trials; 2008; 5(1):61-9. PubMed ID: 18283082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grinding to a halt: the effects of the increasing regulatory burden on research and quality improvement efforts.
    Infectious Diseases Society of America
    Clin Infect Dis; 2009 Aug; 49(3):328-35. PubMed ID: 19566438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethical challenges in neonatal research: Summary report of the ethics group of the newborn drug development initiative.
    Baer GR; Nelson RM;
    Clin Ther; 2006 Sep; 28(9):1399-407. PubMed ID: 17062312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conducting clinical trials in Singapore.
    Woo KT
    Singapore Med J; 1999 Apr; 40(4):310-3. PubMed ID: 10487091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The other side of clinical trial monitoring; assuring data quality and procedural adherence.
    Williams GW
    Clin Trials; 2006; 3(6):530-7. PubMed ID: 17170037
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-based interventions for neurologic conditions: ethical challenges for early human trials.
    Mathews DJ; Sugarman J; Bok H; Blass DM; Coyle JT; Duggan P; Finkel J; Greely HT; Hillis A; Hoke A; Johnson R; Johnston M; Kahn J; Kerr D; Kurtzberg J; Liao SM; McDonald JW; McKhann G; Nelson KB; Rao M; Regenberg A; Siegel AW; Smith K; Solter D; Song H; Vescovi A; Young W; Gearhart JD; Faden R
    Neurology; 2008 Jul; 71(4):288-93. PubMed ID: 18463365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The inspection by the Danish Medical Products Agency of drug clinical trials].
    Jacobsen E; Stilbo I
    Ugeskr Laeger; 2003 Apr; 165(16):1656-8. PubMed ID: 12756822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Problems in the conduct and analysis of randomized clinical trials. Are we getting the right answers to the wrong questions?
    Rabeneck L; Viscoli CM; Horwitz RI
    Arch Intern Med; 1992 Mar; 152(3):507-12. PubMed ID: 1546913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Establishing pan-European clinical trials: regulatory compliance and other practical considerations.
    Grienenberger A
    J Biolaw Bus; 2004; 7(4):58-63. PubMed ID: 15675097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoepidemiology 101: data monitoring committees in the post-marketing approval setting.
    Lilienfeld DE
    Pharmacoepidemiol Drug Saf; 2004 Jun; 13(6):381-5. PubMed ID: 15170767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection of human subjects; standards for institutional review boards for clinical investigations--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(17 pt 2):8958-79. PubMed ID: 10249529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
    EFSA GMO Panel Working Group on Animal Feeding Trials
    Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Controlled randomized clinical trials].
    Jaillon P
    Bull Acad Natl Med; 2007; 191(4-5):739-56; discussion 756-8. PubMed ID: 18225427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.